Catalent surges on $16.5 billion takeover by Novo Nordisk shareholder

Shares in drug manufacturer Catalent Inc (NYSE:CTLT) soared over 11% in pre-market trading as news broke that Novo Nordisk (NYSE:NVO)’s controlling shareholder was to buy the firm for US$16.5 billion. Novo Holdings, which owns a majority stake in the weight-loss drug maker, unveiled the takeover on Monday, which includes assumed debt and, at US$63.50 a share, represents a 16.5% premium on Catalent’s Friday closing price. Novo Nordisk (NYSE:NVO), Europe’s largest company by market cap, will take control of t ...